Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ashley V. Ward"'
Autor:
Ashley V. Ward, Shawna B. Matthews, Lynsey M. Fettig, Duncan Riley, Jessica Finlay-Schultz, Peter Kabos, Matthew Jackman, Paul S. MacLean, Carol A. Sartorius
Metabolic reprogramming remains largely understudied in relation to hormones in estrogen receptor (ER) and progesterone receptor (PR) positive breast cancer. In this study, we investigated how estrogens, progestins, or the combination, impact metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7639ecc435ccfd3320f0ce7d49209482
https://doi.org/10.21203/rs.2.23619/v3
https://doi.org/10.21203/rs.2.23619/v3
Autor:
Ashley V. Ward, Shawna B. Matthews, Lynsey M. Fettig, Duncan Riley, Jessica Finlay-Schultz, Kiran V. Paul, Matthew Jackman, Peter Kabos, Paul S. MacLean, Carol A. Sartorius
Publikováno v:
Cancers; Volume 14; Issue 7; Pages: 1776
Metabolic reprogramming remains largely understudied in relation to hormones in estrogen receptor (ER) and progesterone receptor (PR) positive breast cancer. In this study, we investigated how estrogens, progestins, or the combination, impact metabol
Autor:
Kiran V. Paul, Olivia McGinn, Ashley V. Ward, Lynsey M. Fettig, Peter Kabos, Jessica Finlay-Schultz, Carol A. Sartorius, Duncan Riley, Joshua J. Ivie
Publikováno v:
Oncogene
Estrogen receptor (ER) positive breast cancers often contain subpopulations of cells that express the intermediate filament protein cytokeratin 5 (CK5). CK5+ cells are enriched in cancer stem cell (CSC) properties, can be induced by progestins, and p
Publikováno v:
J Mammary Gland Biol Neoplasia
Abnormal lipid metabolism is common in breast cancer with the three main subtypes, hormone receptor (HR) positive, human epidermal growth factor 2 (HER2) positive, and triple negative, showing common and distinct lipid dependencies. A growing body of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ca7da339983619f06af3a8ad5ada59
https://europepmc.org/articles/PMC8883833/
https://europepmc.org/articles/PMC8883833/
Autor:
Matthew Jackman, Paul S. MacLean, Peter Kabos, Ashley V. Ward, Shawna B. Matthews, Lynsey M. Fettig, Carol A. Sartorius, Jessica Finlay-Schultz
Progesterone receptors (PR) profoundly influence breast cancer biology by modifying estrogen receptor (ER) gene regulation, and, under some contexts, increasing populations of cancer stem cells. Abnormal metabolism is a cancer hallmark that has large
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::198ecd9cca5f696de14ce582783040f4
https://doi.org/10.21203/rs.2.23619/v2
https://doi.org/10.21203/rs.2.23619/v2
Autor:
Matthew Jackman, Paul S. MacLean, Ashley V. Ward, Peter Kabos, Lynsey M. Fettig, Carol A. Sartorius, Shawna B. Matthews, Jessica Finlay-Schultz
Background Progestins generally suppress the growth of estrogen receptor (ER) and progesterone receptor (PR) positive breast cancers and are occasionally used as treatments. However, progestins also increase populations of therapy-resistant cancer st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::530ef48ff22a3f55f90455206ccf0cf5
https://doi.org/10.21203/rs.2.23619/v1
https://doi.org/10.21203/rs.2.23619/v1
Autor:
Ashley V. Ward, Carol A. Sartorius, Jessica Finlay-Schultz, Kiran V. Paul, Peter Kabos, Olivia McGinn
Publikováno v:
Cancer Research. 80:2605-2605
Breast cancer (BC) is clinically classified according to expression of estrogen receptor, progesterone receptor (ER+ BC), HER2 (HER2+), or absence of these markers (triple negative BC). While TNBC has the inferior prognosis in the short term, ER+ bre
Autor:
Shawna B. Matthews, Lynsey M. Fettig, Ashley V. Ward, Matthew R. Jackman, Paul S. MacLean, Carol A. Sartorius
Publikováno v:
Cancer Research. 79:796-796
The dichotomous nature of progesterone receptor (PR) in estrogen receptor (ER)-positive breast cancers has confounded its use as an endocrine target. Historically, progestins were used to treat some advanced breast cancers and ongoing clinical trials